{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:53:43Z","timestamp":1788292423884,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["S2017\/BMD-3733-2"],"award-info":[{"award-number":["S2017\/BMD-3733-2"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["[RTI2018-093569-B-I00"],"award-info":[{"award-number":["[RTI2018-093569-B-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2AI112193"],"award-info":[{"award-number":["DP2AI112193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    High grade non-muscle-invasive bladder tumours are treated with transurethral resection followed by recurrent intravesical instillations of Bacillus Calmette Gu\u00e9rin (BCG). Although most bladder cancer patients respond well to BCG, there is no clinical parameter predictive of treatment response, and when treatment fails, the prognosis is very poor. Further, a high percentage of NMIBC patients treated with BCG suffer unwanted effects that force them to stop treatment. Thus, early identification of patients in which BCG treatment will fail is really important. Here, to identify early stage non-invasive biomarkers of non-responder patients and patients at risk of abandoning the treatment, we longitudinally analysed the phenotype of cells released into the urine of bladder cancer patients 3-7 days after BCG instillations. Mass cytometry (CyTOF) analyses revealed a large proportion of granulocytes and monocytes, mostly expressing activation markers. A novel population of CD15\n                    <jats:sup>+<\/jats:sup>\n                    CD66b\n                    <jats:sup>+<\/jats:sup>\n                    CD14\n                    <jats:sup>+<\/jats:sup>\n                    CD16\n                    <jats:sup>+<\/jats:sup>\n                    cells was highly abundant in several samples; expression of these markers was confirmed using flow cytometry and qPCR. A stronger inflammatory response was associated with increased cell numbers in the urine; this was not due to hematuria because the cell proportions were distinct from those in the blood. This pilot study represents the first CyTOF analysis of cells recruited to urine during BCG treatment, allowing identification of informative markers associated with treatment response for sub-selection of markers to confirm using conventional techniques. Further studies should jointly evaluate cells and soluble factors in urine in larger cohorts of patients to characterise the arms of the immune response activated in responders and to identify patients at risk of complications from BCG treatment.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.970931","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:19:21Z","timestamp":1663215561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Eva","family":"Castellano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Samba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Esteso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vendrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Garc\u00eda\u2010Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"L\u00f3pez\u2010Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"\u00c1lvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asier","family":"Leibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanmayi","family":"Ranganath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh T.","family":"Reyburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mart\u00ednez\u2010Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Blish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Val\u00e9s\u2010G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: A global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus calmette-guerin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.001","article-title":"How well can you actually predict which non\u2013Muscle-Invasive bladder cancer patients will progress","volume":"60","author":"Sylvester","year":"2011","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus calmette-guerin immunotherapy: Are we there yet? a systematic review","volume":"73","author":"Kamat","year":"2017","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus calmette-guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: Incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"Perez-Jacoiste Asin","year":"2014","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/s0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus calmette-guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14793","article-title":"The epidemiology of bacille calmette-guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study","volume":"124","author":"Larsen","year":"2019","journal-title":"BJU Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"And risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070940","article-title":"BCG Therapy of bladder cancer stimulates a prolonged release of the chemoattractant CXCL10 (IP10) in patient urine","volume":"11","author":"Ashiru","year":"2019","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer-a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective bacillus calmette-guerin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1242\/bio.032045","article-title":"Enhanced survival of BCG-stimulated dendritic cells: Involvement of anti-apoptotic proteins and NF-kappaB","volume":"7","author":"Kumar","year":"2018","journal-title":"Biol Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000052497","article-title":"Activation of natural killer cells by bacillus calmette-guerin","volume":"39","author":"Brandau","year":"2001","journal-title":"Eur Urol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/2162402X.2017.1293212","article-title":"NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-Activated NK cells and BCG promotes NK cell activation","volume":"6","author":"Garcia-Cuesta","year":"2015","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1293212","article-title":"Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes","volume":"6","author":"Garcia-Cuesta","year":"2017","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus calmette-guerin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"297ra115","DOI":"10.1126\/scitranslmed.aac5722","article-title":"Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility","volume":"7","author":"Strauss-Albee","year":"2015","journal-title":"Sci Trans Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22271","article-title":"Normalization of mass cytometry data with bead standards","volume":"83","author":"Finck","year":"2013","journal-title":"Cytometry A"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia","volume":"31","author":"Amir el","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1364\/BOE.6.000977","article-title":"Detection of urinary bladder cancer cells using redox ratio and double excitation wavelengths autofluorescence","volume":"6","author":"Palmer","year":"2015","journal-title":"BioMed Opt Express"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22067","article-title":"A platinum-based covalent viability reagent for single-cell mass cytometry","volume":"81","author":"Fienberg","year":"2012","journal-title":"Cytometry A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6230409","DOI":"10.1155\/2019\/6230409","article-title":"Clinical spectrum of complications induced by intravesical immunotherapy of bacillus calmette-guerin for bladder cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: Roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803831","article-title":"IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients","volume":"182","author":"Mandruzzato","year":"2009","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60083","article-title":"STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients","volume":"123","author":"Vasquez-Dunddel","year":"2013","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552463","article-title":"Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS","volume":"124","author":"Keerthivasan","year":"2014","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.001","article-title":"Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer","volume":"30","author":"Singhal","year":"2016","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.970931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:19:26Z","timestamp":1663215566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.970931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.970931"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.970931","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.12.147710","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"970931"}}